Skip to main content

Table 3 Intra-observer agreement analysis of tumor maximum width measurements

From: Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging

 

HRCVTMR vs. HRCTVTRUS

 

ICC

CI 95%

All stages

Obs. 1

0.96

[0.94–0.97]

Obs. 2

0.93

[0.90–0.95]

Obs. 3

0.96

[0.95–0.98]

FIGO I

Obs. 1

0.95

[0.87–0.98]

Obs. 2

0.98

[0.94–0.99]

Obs. 3

0.97

[0.92–0.99]

FIGO II

Obs. 1

0.94

[0.9–0.96]

Obs. 2

0.97

[0.95–0.98]

Obs. 3

0.9

[0.85–0.94]

FIGO III

Obs. 1

0.91

[0.75–0.97]

Obs. 2

0.7

[0.3–0.89]

Obs. 3

0.98

[0.94–0.99]

FIGO IV

Obs. 1

0.87

[0.57–0.96]

Obs. 2

0.82

[0.44–0.95]

Obs. 3

0.93

[0.76–0.98]

  1. Note that: ICC > 0,75: excellent agreement; 0,4 – 0,75: fair to good agreement; < 0,4: poor agreement
  2. Abbreviations: HRCTVMR High risk clinical target volume maximum width measured at preBT MR, HRCTVTRUS Tumor maximum width measured at preBT TRUS, ICC Intra-class Correlation Coefficient, CI Confidence interval, FIGO International Federation of Gynaecology and Obstetrics, Obs Observer
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us